In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma(,)

OBJECTIVE: Poly(ADP-ribose) polymerase (PARP) inhibitors have yielded encouraging responses in high-grade serous ovarian carcinomas (HGSOCs), but the optimal treatment setting remains unknown. We assessed the effect of niraparib on HGSOC patient-derived xenograft (PDX) models as well as the relation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecol Oncol
Hauptverfasser: AlHilli, Mariam M., Becker, Marc A., Weroha, S. John, Flatten, Karen S., Hurley, Rachel M., Harrell, Maria I., Oberg, Ann L., Maurer, Matt J., Hawthorne, Kieran M., Hou, Xiaonan, Harrington, Sean C., McKinstry, Sarah, Meng, X. Wei, Wilcoxen, Keith M., Kalli, Kimberly R., Swisher, Elizabeth M., Kaufmann, Scott H., Haluska, Paul
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370566/
https://ncbi.nlm.nih.gov/pubmed/27614696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.08.328
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge